Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

U.S. FDA approves Sanofi's bleeding disorder therapy

Published 02/23/2023, 06:53 PM
Updated 02/24/2023, 06:51 AM
© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier/
BARC
-
BAYGN
-
BIIB
-
SNY
-
NVO
-

By Sriparna Roy and Khushi Mandowara

(Reuters) -The U.S. Food and Drug Administration has approved Sanofi (NASDAQ:SNY) SA's therapy to treat a type of inherited bleeding disorder known as hemophilia A and expects to launch it in the United States in April, the French drugmaker said on Thursday.

Sanofi's replacement therapy – Altuviiio – is entering a market dominated by rivals like Takeda Pharmaceutical, Bayer AG (ETR:BAYGN) and Novo Nordisk (NYSE:NVO), which sell factor replacement therapies that have been the standard treatment for decades.

Factor replacement therapies replace the missing blood clotting factor so that blood can clot properly by injecting treatment products into a person's vein.

Sanofi's drug is likely to be considered one of the best in that class, said Damien Conover, Morningstar analyst, ahead of the approval.

"We see 2.3 billion euros of peak sales globally," said Barclays (LON:BARC) analyst Emily Field.

The average annual cost of existing clotting factor therapies is roughly $300,000, and at least two analysts ahead of the approval estimated the price of Sanofi's drug to be slightly at a premium to the traditional factor therapies.

Sanofi, which developed the drug along with Swedish drugmaker Sobi, said it will price Altuviiio at parity to the annual cost of treating a prophylaxis patient on Eloctate.

The French drugmaker gained access to Elocate and Altuviiio through a $11.6-billion buyout of U.S. hemophilia specialist Bioverativ in 2018, which was separated from Biogen Inc (NASDAQ:BIIB).

The FDA approval also provides patients an alternative to Roche's blockbuster drug, Hemlibra, which is the market leader for this indication.

© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier/

"I think that most doctors are thinking that at least in the first couple of years of the launch Altuviiio would only take share from the other factor therapies and not from Hemlibra," said Field.

Hemophilia A is a genetic disorder caused by missing or defective factor VIII, a clotting protein.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.